LOGIN  |  REGISTER
Recursion
Recursion

AirSculpt Technologies Announces First Quarter 2023 Earnings Release Date and Conference Call

April 28, 2023 | Last Trade: US$6.45 0.22 -3.30

MIAMI BEACH, Fla., April 28, 2023 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), a national provider of premium body contouring procedures, today announced it will report first quarter 2023 financial results before market open on Friday, May 12, 2023, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time.

The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13738277 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.elitebodysculpture.com. A replay of the webcast will be available for approximately 90 days.

About AirSculpt Technologies

AirSculpt Technologies (NASDAQ: AIRS) is an experienced, fast-growing national provider of body contouring procedures delivering a premium consumer experience under its brand, Elite Body Sculpture. At Elite Body Sculpture, we provide custom body contouring using our proprietary AirSculpt® method that removes unwanted fat in a minimally invasive procedure, producing dramatic results. It is our mission to generate the best results for our patients.

Investor Contact:

Steven Halper/Caroline Paul
Managing Directors, LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:

Stephanie Evans Greene
Chief Marketing Officer
AirSculpt Technologies, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page